Johnson & Johnson is intensifying its efforts to expand the market footprint of Spravato (esketamine) for treatment-resistant depression (TRD), leveraging…
Read More
J&J Poster Puts Spravato Remission Data at Center of Treatment-Resistant Depression Growth Push
More than six decades after Calvin Stevens first synthesized ketamine at Parke-Davis while searching for a safer anesthetic, the molecule…
Read More
European Commission Approves Keytruda Combination Therapy for PD-L1-Positive Platinum-Resistant Ovarian Cancer
The European Commission (EC) has granted approval for Keytruda (pembrolizumab) in combination with paclitaxel, with or without bevacizumab, as a…
Read More
First Phase 3 psilocybin data clears the bar for treatment-resistant depression, but how high was the bar?
For decades, successive waves of antidepressants have promised relief to millions suffering from mood disorders, yet the landscape for those…
Read More
First Phase 3 psilocybin data clears the bar for treatment-resistant depression, but how high was the bar?
For decades, the medical community has grappled with the persistent challenge of mood disorders, offering successive waves of antidepressants that,…
Read More
First Phase 3 psilocybin data clears the bar for treatment-resistant depression, but how high was the bar?
The landscape of mental health treatment witnessed a significant development on February 17, 2026, as Compass Pathways, a leading mental…
Read More
